# Olmesartan in Essential Hypertension

> **NCT00185172** · PHASE3 · COMPLETED · sponsor: **Sankyo Pharma Gmbh** · enrollment: 2333 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **OTHER:** placebo
- **DRUG:** olmesartan medoxomil
- **DRUG:** olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets

## Key facts

- **NCT ID:** NCT00185172
- **Lead sponsor:** Sankyo Pharma Gmbh
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 2333 (ACTUAL)
- **Last updated:** 2008-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185172, "Olmesartan in Essential Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00185172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*